1
|
González‐Domínguez A, Cristobal‐Verdejo JI, López‐Espinar C, Fontela‐González S, Vázquez S, Justo‐Domínguez J, González‐Caramazana J, Bragado‐Cuesta M, Álvarez‐Punzano A, Herrería‐Bustillo VJ. Retrospective evaluation of hematological ratios in canine parvovirosis: 401 cases. J Vet Intern Med 2024; 38:161-166. [PMID: 38100467 PMCID: PMC10800196 DOI: 10.1111/jvim.16972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 12/01/2023] [Indexed: 12/17/2023] Open
Abstract
BACKGROUND The utility of neutrophil-to-lymphocyte ratio (NLR), platelet to-lymphocyte ratio (PLR) and monocyte-to-lymphocyte ratio (MLR) as prognostic indicators has not been investigated in canine parvovirosis (CPV). HYPOTHESIS To evaluate whether these hematological ratios obtained at hospital admission in CPV are associated with outcome or duration of hospitalization. ANIMALS Four hundred one client-owned dogs presented with CPV. Methods-Retrospective multicenter cohort study. Medical records were reviewed to identify dogs with CPV. Data regarding signalment, complete blood count at admission, duration of hospitalization and outcome were collected. RESULTS Of the 401 dogs included in the study, 336 (83.8%) survived to discharge. The median (25th and 75th percentiles) PLR in nonsurvivors (336.56 [159.84-635.77]) was significantly higher than in survivors (217.65 [117.67-389.65]) (P = .003). The area under the receiver-operating characteristic curve for nonsurvival was 0.615 (95% CI [0.593-0.691], P = .003). A cut off of 700 showed a 21.5% sensitivity and 90% specificity for nonsurvival. No association was observed between hospitalization duration and either hematological ratios or total WBC counts. The median (25th and 75th percentiles) lymphocyte count was below reference interval in all dogs and was significantly lower in the dogs which died (0.82 × 109 /L [0.5-1.87]) than in survivors (1.27 × 109 /L [0.73-2.22]) (P = .005). The median (25th and 75th percentiles) monocyte count however was lower in survivors (0.38 × 109 /L [0.29-1.59]), than in nonsurvivors (0.73 × 109 /L [0.1-2]) (P = .002). CONCLUSIONS Evaluation of PLR at hospital admission might be a useful marker of disease severity and could have prognostic value in dogs with CPV.
Collapse
Affiliation(s)
- Andrea González‐Domínguez
- Veterinary Teaching Hospital of the Catholic University of Valencia—Emergency and critical careValenciaSpain
- Universidad de Leon—Veterinary Teaching Hospital, Emergency and Critical CareLeonCastilla y LeónSpain
| | | | | | | | - Sergio Vázquez
- Servicio de Oncología, IVC Evidensia Aúna Especialidades VeterinariasValenciaSpain
| | | | | | | | - Alicia Álvarez‐Punzano
- Veterinary Teaching Hospital of the Alfonso X El Sabio—Emergency and Critical CareMadridSpain
| | | |
Collapse
|
2
|
Garcia‐de la Virgen M, López‐Almela I, Moura A, Vázquez S, Perez‐Montagud S, Leclercq A, Lecuit M, Quereda JJ. Clinical and genomic features of Listeria monocytogenes-associated mesenteric lymphadenitis in a cat. J Vet Intern Med 2024; 38:363-369. [PMID: 38051604 PMCID: PMC10800189 DOI: 10.1111/jvim.16961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 11/17/2023] [Indexed: 12/07/2023] Open
Abstract
BACKGROUND Listeriosis is a severe foodborne infection caused by Listeria monocytogenes, an important foodborne pathogen of animals and humans. Listeriosis is a rare disease in cats. OBJECTIVE To describe the clinical, diagnostic imaging, histological, and microbiological features of L. monocytogenes-associated mesenteric lymphadenitis in a cat. ANIMALS Listeria monocytogenes-associated mesenteric lymphadenitis was confirmed in a cat by histology and microbiology. RESULTS Two distinct isolates of L. monocytogenes were cultured from the affected mesenteric lymph node and whole genome sequencing was performed. CONCLUSION AND CLINICAL IMPORTANCE This report should alert veterinary clinicians and microbiologists to the syndrome, which may have implications for health and food safety in animals and humans.
Collapse
Affiliation(s)
| | - Inmaculada López‐Almela
- Research Group Intracellular Pathogens: Biology and Infection, Departamento Producción y Sanidad Animal, Salud Pública Veterinaria y Ciencia y Tecnología de los Alimentos, Facultad de VeterinariaUniversidad Cardenal Herrera‐CEU, CEU UniversitiesValenciaSpain
| | - Alexandra Moura
- Institut Pasteur, National Reference Centre and WHO Collaborating Centre ListeriaParisFrance
- Institut Pasteur, Université Paris Cité, Inserm U1117, Biology of Infection UnitParisFrance
| | - Sergio Vázquez
- Servicio de Oncología, IVC Evidensia Aúna Especialidades VeterinariasValenciaSpain
| | - Sara Perez‐Montagud
- Hospital Clínico Veterinario, Facultad de VeterinariaUniversidad Cardenal Herrera‐CEU, CEU UniversitiesValenciaSpain
| | - Alexandre Leclercq
- Institut Pasteur, National Reference Centre and WHO Collaborating Centre ListeriaParisFrance
- Institut Pasteur, Université Paris Cité, Inserm U1117, Biology of Infection UnitParisFrance
| | - Marc Lecuit
- Institut Pasteur, National Reference Centre and WHO Collaborating Centre ListeriaParisFrance
- Institut Pasteur, Université Paris Cité, Inserm U1117, Biology of Infection UnitParisFrance
- Necker‐Enfants Malades University Hospital, Division of Infectious Diseases and Tropical MedicineInstitut Imagine, APHPParisFrance
| | - Juan J Quereda
- Research Group Intracellular Pathogens: Biology and Infection, Departamento Producción y Sanidad Animal, Salud Pública Veterinaria y Ciencia y Tecnología de los Alimentos, Facultad de VeterinariaUniversidad Cardenal Herrera‐CEU, CEU UniversitiesValenciaSpain
| |
Collapse
|
3
|
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial. Clin Transl Oncol 2023:10.1007/s12094-023-03358-4. [PMID: 38102374 DOI: 10.1007/s12094-023-03358-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Accepted: 11/16/2023] [Indexed: 12/17/2023]
Abstract
PURPOSE Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for overall survival (OS), and additional analyses of survival per a different PD-L1 expression cutoff of ≥ 1% in tumor cells or immune cells (TC/IC). METHODS JAVELIN Bladder 100 data were used for the analysis of the interaction by PD-L1 status (per cutoff used in the trial) for OS and, additionally, OS and progression-free survival (PFS) analyses per a different ≥ 1% TC/IC PD-L1 expression cutoff (Ventana SP263 assay). RESULTS No significant interaction between treatment and PD-L1 status was observed for OS. Clinically meaningful and robust survival data were observed in favor of avelumab using the different ≥ 1% TC/IC PD-L1 expression cutoff. CONCLUSIONS These results demonstrate the benefit of avelumab maintenance in la/mUC regardless of PD-L1 expression, consistent with approved labels.
Collapse
Affiliation(s)
| | - Carlos Álvarez
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Pablo Maroto
- Hospital Universitari de La Santa Creu I Sant Pau, Barcelona, Spain
| | | | - María José Méndez-Vidal
- Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital (HURS), Cordoba, Spain
| | | | - Javier Puente
- Hospital Universitario Clínico San Carlos, Madrid, Spain
| | | | | | | | | | | | | | - Craig Davis
- Pfizer Translational Oncology, La Jolla, CA, USA
| | | | | | | |
Collapse
|
4
|
Aparicio I, Iranzo P, Reyes R, Bote H, Saigi M, Bringas M, Bosch-Barrera J, Corral J, Aparisi F, Ruffinelli JC, Jiménez B, Lage Y, López-Castro R, Majem M, Vázquez S, Artal Á, Rodríguez-Pérez Á, Lázaro-Quintela M, Torres JMS, Reguart N, Cucurull M, Gil-Bazo I, Camps C, Nadal E, Del Barrio A, Garrido P, Dómine M, Álvarez R, Muñoz AJ, Calles A. Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer. Thromb Res 2023; 232:133-137. [PMID: 37976733 DOI: 10.1016/j.thromres.2023.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 10/31/2023] [Accepted: 11/06/2023] [Indexed: 11/19/2023]
Abstract
INTRODUCTION We aimed to determine if advanced BRAF-mutant NSCLC has a higher thromboembolic events (TEE) rate than the expected. METHODS Between 2008 and 2021, 182 patients with BRAF-mutant advanced NSCLC (BRAF V600E, n = 70; BRAF non-V600E, n = 112) were retrospectively identified from 18 centers in Spain. Patients received chemotherapy (n = 147), immunotherapy (n = 69), targeted therapy (n = 42), and immunotherapy + chemotherapy (n = 26). RESULTS Incidence rate of TEE was 26.4 % (95%CI: 19.9 %-32.9 %). A total of 72 TEE were documented among 48 patients, as 18 patients (37.5 %) developed more than one event. Median time to TEE onset was 2 months, 69 % of TEE occurred in the peridiagnostic period (+/- 90 days from cancer diagnosis), and in 16 pts. (33 %) TEE was the form of lung cancer presentation. Although most TEE were only venous (82 %; PE, n = 33; DVT, n = 16), arterial events were reported in 31 % and occurred earlier, or TEE presented in atypical locations (13.9 %). TEE were related to high hospitalization rate (59 %), recurrence (23 %), and mortality (10.4 %) despite appropriate anticoagulant/antiaggregant treatment. Median OS in patients without-TEE was 19.4 months (95%CI: 4.6-34.1), and significantly shorter in patients with arterial-TEE vs venous-TEE vs both of them: 9.9 months (95%CI: 0-23.5) vs 41.7 months (95%CI: 11.3-72.2 m) vs 2.7 months (95%CI: 2.1-3.3), p = 0.001. Neither clinical or molecular features (BRAF V600E/non-V600E), nor cancer treatment was associated to TEE occurrence. Khorana score underperformed to predict thrombosis at cancer diagnosis, as only 19.2 % of patients were classified as high-risk. CONCLUSIONS Thrombotic events represent a new clinical feature of BRAF-mutant lung cancer. Patients with almost a 30 % incidence of TEE should be offered systematic anticoagulation.
Collapse
Affiliation(s)
- Inmaculada Aparicio
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain; Facultad de Medicina, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain
| | - Patricia Iranzo
- Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Roxana Reyes
- Medical Oncology Department, Thoracic Oncology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Helena Bote
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain;-H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain
| | - María Saigi
- Medical Oncology Department, Hospital Germans Trías i Pujol, Institut Català d'Oncologia-ICO, Badalona, Barcelona, Spain
| | - Marianela Bringas
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
| | - Joaquim Bosch-Barrera
- Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, 17007 Girona, Spain. Precision Oncology Group (OncoGIR-Pro), Institut d'Investigació Biomèdica de Girona (IDIBGI), 17190, Salt, Spain
| | - Jesús Corral
- Clínica Universidad de Navarra, Department of Oncology, Pamplona, Spain
| | - Francisco Aparisi
- Medical Oncology Department, Hospital General Universitario de Valencia, Department of Medicine, Universitat de València, TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia. CIBERONC, Valencia, Spain
| | - Jose C Ruffinelli
- Medical Oncology Department, Centre Sanitari i Universitari de Bellvitge, Institut Català d'Oncologia (-ICO), L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Yolanda Lage
- Medical Oncology Department; Ramón y Cajal University Hospital, Madrid, Spain
| | | | - Margarita Majem
- Department of Medical Oncology; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Sergio Vázquez
- Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - Ángel Artal
- Medical Oncology Service, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - Ángel Rodríguez-Pérez
- Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | | | - Noemí Reguart
- Medical Oncology Department, Thoracic Oncology Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - Marc Cucurull
- Medical Oncology Department, Hospital Germans Trías i Pujol, Institut Català d'Oncologia-ICO, Badalona, Barcelona, Spain
| | - Ignacio Gil-Bazo
- Clínica Universidad de Navarra, Department of Oncology, Pamplona, Spain; Instituto Valenciano de Oncología, Department of Oncology, Valencia, Spain
| | - Carlos Camps
- Medical Oncology Department, Hospital General Universitario de Valencia, Department of Medicine, Universitat de València, TRIAL Mixed Unit, Centro Investigación Príncipe Felipe-Fundación Investigación Hospital General Universitario de Valencia. CIBERONC, Valencia, Spain
| | - Ernest Nadal
- Medical Oncology Department, Centre Sanitari i Universitari de Bellvitge, Institut Català d'Oncologia (-ICO), L'Hospitalet de Llobregat, Barcelona, Spain
| | | | - Pilar Garrido
- Medical Oncology Department; Ramón y Cajal University Hospital, Madrid, Spain
| | - Manuel Dómine
- Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Rosa Álvarez
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
| | - Andrés J Muñoz
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain
| | - Antonio Calles
- Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.
| |
Collapse
|
5
|
Carles J, Alonso-Gordoa T, Mellado B, Méndez-Vidal MJ, Vázquez S, González-Del-Alba A, Piulats JM, Borrega P, Gallardo E, Morales-Barrera R, Paredes P, Reig O, Garcías de España C, Collado R, Bonfill T, Suárez C, Sampayo-Cordero M, Malfettone A, Garde J. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. Eur J Cancer 2022; 173:317-326. [PMID: 35981452 DOI: 10.1016/j.ejca.2022.06.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 06/27/2022] [Accepted: 06/29/2022] [Indexed: 11/25/2022]
Abstract
PURPOSE The paper aims to evaluate the efficacy and safety of 223Ra in patients who progressed after first-line androgen deprivation therapy. PATIENTS AND METHODS EXCAAPE (NCT03002220) was a multicentre, single-arm, open-label, non-controlled phase IIa trial in 52 patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases who have progressed on abiraterone acetate or enzalutamide, up to six doses of 223Ra (55 kBq/kg of body weight per month). The primary end-point was radiographic progression-free survival (rPFS). Secondary end-points included rPFS based on androgen receptor splice variant 7 (AR-V7) expression in circulating tumour cells (CTCs), overall survival, and safety. RESULTS Median rPFS was 5.5 months (95% CI 5.3-5.5). Median rPFS of patients with AR-V7(-) CTCs was longer than that of patients with AR-V7(+) CTCs (5.5 versus 2.2 months, respectively; P = 0.056). Median overall survival was 14.8 months (95% CI 11.2-not reached) and was significantly greater for AR-V7(-) patients than for AR-V7(+) patients (14.8 months versus 3.5 months, respectively; P < 0.01). 223Ra was well tolerated; anaemia and thrombocytopenia were the most common grade 3/4 adverse events (5.8% and 11.5%, respectively). CONCLUSIONS 223Ra seems to be a reasonable treatment for patients with metastatic castration-resistant prostate cancer and asymptomatic bone metastases progressing on novel hormonal therapy and had an acceptable safety profile.
Collapse
Affiliation(s)
- Joan Carles
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain.
| | - Teresa Alonso-Gordoa
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Begoña Mellado
- Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - María J Méndez-Vidal
- Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), Córdoba, Spain; Reina Sofía University Hospital (HURS), Córdoba, Spain
| | | | | | | | | | - Enrique Gallardo
- Parc Taulí University Hospital, Parc Taulí Institute of Research and Innovation I3PT, Barcelona, Spain
| | - Rafael Morales-Barrera
- Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Universitat Autónoma de Barcelona, Barcelona, Spain
| | - Pilar Paredes
- Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Oscar Reig
- Medical Oncology Department, Hospital Clínic Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | | | - Cristina Suárez
- Universitat Autónoma de Barcelona, Barcelona, Spain; Parc Taulí University Hospital, Parc Taulí Institute of Research and Innovation I3PT, Barcelona, Spain
| | | | | | - Javier Garde
- Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain
| |
Collapse
|
6
|
Nadal E, Cantero A, Ortega A, Dómine M, Barba A, Blasco A, García J, Mosquera J, Vázquez S, Rodríguez D, López-Castro R, Juan-Vidal O, Sánchez A, Paz-Ares L, Hernández A, Iranzo P, Diz P, Provencio M, Simó M, Navarro V, Bruna J. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Bellmunt J, Valderrama BP, Puente J, Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ, del Muro XG, Arranz JÁ, Durán I. Recent Therapeutic Advances in Urothelial Carcinoma: A Paradigm Shift in Disease Management. Crit Rev Oncol Hematol 2022; 174:103683. [DOI: 10.1016/j.critrevonc.2022.103683] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 04/07/2022] [Accepted: 04/11/2022] [Indexed: 12/13/2022] Open
|
8
|
Espinosa J, Vázquez S, Millán-Varela L, Prada I, Ferreras M, Pérez V. Severe Hypertrophy and Hyperplasia of Muscular and Serosal Layers Associated with Intestinal Lipogranulomatous Lymphangitis in Two Dogs. J Comp Pathol 2022. [DOI: 10.1016/j.jcpa.2021.11.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G, Estival A, Calvo V, Jiménez B, Arasanz H, Coves J, Majem M, Massutí B, Vázquez S, Juan-Vidal O, Collazo-Lorduy A, Gozálvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, López-Martin A, Córdoba JF, de Asís Aparisi F, Zafra M, Mosquera J, Pérez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martín P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res 2022; 11:53-63. [PMID: 35242627 PMCID: PMC8825652 DOI: 10.21037/tlcr-21-504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 10/18/2021] [Indexed: 11/18/2022]
Abstract
Background At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response. Methods This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using enzyme-linked immunosorbent assay (ELISA) kit from NovaLisa whose Abs target the recombinant antigen N of the nucleocapsid of SARS-CoV-2. The first Ab determination was performed between April 21 and June 3, 2020. The second Ab determination was performed in all previously seropositive patients, between September 10 and November 20, 2020. Study objectives were to prospectively determine seroprevalence in unselected lung cancer patients during the first wave of the pandemic; the persistence of immunity; protection or lack thereof against reinfection; and the influence of treatments on maintenance or loss of immunity. Results Of 1,500 patients, 128 were seropositive, overall prevalence of 8.5% seropositivity [95% confidence interval (CI): 7.2–10.1%]. Seventy-five percent were in active cancer treatment. Forty-seven point seven percent of IgG positive participants had experienced a symptomatic illness suspected of being infected with SARS-CoV-2 (95% CI: 38.8–56.6%). A second determination was performed on average 4.5 months later [interquartile range (IQR), 4.0–5.0 months] and obtained for 104 of the initially seropositive patients (81%), it could not be obtained in 24 patients, the majority due to death caused by disease progression (73%). In the second determination, IgG was not detected in 30.8% of patients. The severity of the infection, the need for hospitalization (P=0.032) and the presence of symptoms at diagnosis (P=0.02) were associated with persistence of immunity in the second determination. No variables or treatments received were associated with Abs loss. Conclusions Immunity against SARS-CoV-2 does not appear to be compromised by treatment and persists beyond 4 months. Neither do mortality rates appear to be particularly high in this unselected population. Trial Registration ClinicalTrials.gov identifier: NCT04407143.
Collapse
Affiliation(s)
- Mariano Provencio
- Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Delvys Rodríguez-Abreu
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
| | - Ana L. Ortega
- Medical Oncology Department, Hospital Universitario de Jaén, Jaén, Spain
| | - Gloria Serrano
- Medical Oncology Department, Hospital Universiario Infanta Leonor, Madrid, Spain
| | - Carlos Aguado
- Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain
| | - Fernando Franco
- Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Vanesa Gutierrez
- Medical Oncology Department, Hospital Universitario Regional de Málaga, Málaga, Spain
| | | | - María Guirado
- Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain
| | - Gretel Benítez
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain
| | - Anna Estival
- Catalan Institute of Oncology, Hospital Universitari Germans Trias i Pujol, B-ARGO, IGTP, Badalona, Spain
| | - Virginia Calvo
- Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Beatriz Jiménez
- Medical Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain
| | - Hugo Arasanz
- Medical Oncology Department, Complejo Hospitalario Navarra-Navarrabiomeed, Pamplona, Spain
| | - Juan Coves
- Medical Oncology Department, Hospital Universitari Son LLàtzer, Palma de Mallorca, Spain
| | - Margarita Majem
- Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Bartomeu Massutí
- Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain
| | - Sergio Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - Oscar Juan-Vidal
- Medical Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Ana Collazo-Lorduy
- Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
| | - Clara L. Gozálvez
- Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - Edel Del Barco
- Medical Oncology Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
| | - Adriana Rosero
- Medical Oncology Department, Hospital Universitario Infanta Cristina, Madrid, Spain
| | | | - María A. Moreno
- Medical Oncology Department, Hospital Universitario de Puerto Real, Cádiz, Spain
| | - Xabier Mielgo-Rubio
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - José C. Villa
- Medical Oncology Department, Hospital General Universitario Ciudad Real, Ciudad Real, Spain
| | - Ana López-Martin
- Medical Oncology Department, Hospital Universitario Severo Ochoa, Madrid, Spain
| | - Juan F. Córdoba
- Medical Oncology Department, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | | | - Marta Zafra
- Medical Oncology Department, Hospital General Universitario Morales Messeguer, Murcia, Spain
| | - Joaquín Mosquera
- Medical Oncology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
| | | | - Ernest Nadal
- Medical Oncology Department, Institut Català d’Oncologia, Hospitalet de Llobregat, Barcelona, Spain
| | - Silvia Catot
- Medical Oncology Department, Altaia, Xarxa Assistencial Universitaria Manresa, Barcelona, Spain
| | - José Balsalobre
- Medical Oncology Department, Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain
| | - Teresa de Portugal
- Medical Oncology Department, Complejo Hospitalario de Zamora, Zamora, Spain
| | - Paloma Martín
- Medical Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | | | - Manuel Cobo
- Medical Oncology Department, Hospital Universitario Regional de Málaga, Málaga, Spain
| |
Collapse
|
10
|
Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. Clin Genitourin Cancer 2021; 20:25-34. [PMID: 34789409 DOI: 10.1016/j.clgc.2021.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 09/14/2021] [Accepted: 09/28/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increased benefit from this drug and its combinations still need to be identified. PATIENTS AND METHODS Retrospective multicentre analysis describing clinical characteristics associated with axitinib long-responder (LR) population by comparing two extreme-response sub-groups (progression-free survival [PFS] ≥9 months vs. disease progression/refractory patients [RP]). A multivariate logistic-regression model was used to analyse clinical factors. Efficacy and safety were also analysed. RESULTS In total, 157 patients who received axitinib in second or subsequent line were evaluated (91 LR and 66 RP). Older age at start of axitinib and haemoglobin levels > LLN were independent predictive factors for LR in multivariate analyses. In LR patients, median (m) PFS was 18.1 months, median overall survival was 36.0 months and objective response rate (ORR) was 45.5%. In 59 LR patients receiving axitinib in second-line, mPFS was 18.7 months, mOS was 44.8 months and ORR was 43.9%. mOS was significantly longer in second line compared to subsequent lines (44.8 vs. 26.5 months; P = .009). In LR vs. RP, mPFS with sunitinib in first-line was correlated with mPFS with axitinib in second-line (27.2 vs. 10.9 months P < .001). The safety profile was manageable and consistent with known data. CONCLUSIONS This study confirms the long-term benefits of axitinib in a selected population, helping clinicians to select the best sequential approach and patients who could obtain a greater benefit from axitinib.
Collapse
Affiliation(s)
- Álvaro Pinto
- Medical Oncology Department, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain.
| | - Oscar Reig
- Medical Oncology Department, Hospital Clinic i Provincial, Carrer de Villarroel, 170, 08036 Barcelona, Spain
| | - Clara Iglesias
- Medical Oncology Department, Hospital Universitario Central de Asturias, Avenida Roma, s/n, 33011 Oviedo, Spain
| | - Enrique Gallardo
- Medical Oncology Department, Hospital Universitario Parc Taulí de Sabadell, Parc Taulí, 1, 08208 Sabadell, Barcelona, Spain
| | - Xavier García-Del Muro
- Medical Oncology Department, Institut Català d'Oncologia Hospitalet, IDIBELL Institute of Researh, University of Barcelona, 1, Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Teresa Alonso
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain
| | - Georgia Anguera
- Medical Oncology Department, Nou Hospital De La Santa Creu i Sant Pau, Carrer de Sant Quintí, 89, 08041 Barcelona, Spain
| | - Cristina Suárez
- Medical Oncology Department, Hospital Universitario Vall de Hebrón, Passeig de la Vall d'Hebron, 119, 08035 Barcelona, Spain
| | - José Muñoz-Langa
- Medical Oncology Department, Hospital Universitario La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Spain
| | - Laura Villalobos-León
- Medical Oncology Department, Hospital Universitario Príncipe de Asturias, Carretera de Alcalá, s/n, 28805 Meco, Madrid, Spain
| | - Ángel Rodríguez-Sánchez
- Medical Oncology Department, Hospital Universitario de León, Calle Altos de Nava, s/n, 24071 León, Spain
| | - Nuria Lainez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Calle de Irunlarrea, 3, 31008 Pamplona, Spain
| | - Esther Martínez-Ortega
- Medical Oncology Department , Complejo Hospitalario de Jaén, Avenida del Ejército Español, 10, 23007 Jaén, Spain
| | - Marc Campayo
- Medical Oncology Department, Hospital Universitario MútuaTerrassa, Plaza del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain
| | - Alejandro Velastegui
- Medical Oncology Department, Hospital Universitario Rey Juan Carlos, Calle Gladiolo, s/n, 28933 Móstoles, Madrid, Spain
| | - Alejo Rodriguez-Vida
- Medical Oncology Department, Hospital del Mar, Passeig Marítim 25-29, 08001, Barcelona, Spain
| | - José C Villa-Guzmán
- Medical Oncology Department, Hospital General Universitario de Ciudad Real General, Calle Obispo Rafael Torija, s/n, 13005 Ciudad Real, Spain
| | - Maria J Méndez-Vidal
- Medical Oncology Department, Hospital Universitario Reina Sofía, Avenida Menendez Pidal, 14004, Córdoba, Spain
| | - Gustavo Rubio
- Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Avenida Reyes Católicos, 2, 28040, Madrid, Spain
| | - Iciar García
- Medical Oncology Department, Hospital Virgen de la Salud, Av. de Barber, 30, 45004 Toledo, Spain
| | - Laia Capdevila
- Medical Oncology Department, Hospital San Pablo y Santa Tecla, Rambla Vella, 14, 43003 Tarragona, Spain
| | - Julio Lambea
- Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Avda, Calle de San Juan Bosco, 15, 50009 Zaragoza, Spain
| | - Sergio Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Rúa Dr. Ulises Romero, 1, 27003 Lugo, Spain
| | - Ovidio Fernández
- Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Calle Ramon Puga Noguerol, 54, 32005 Ourense, Spain
| | - Susana Hernando-Polo
- Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Calle Budapest, 1, 28922, Alcorcón, Madrid, Spain
| | - Sara Cerezo
- Medical Oncology Department, Hospital General La Mancha Centro, Av. Constitución, 3, 13600 Alcázar de San Juan, Ciudad Real, Spain
| | - Carmen Santander
- Medical Oncology Department, Hospital Universitario Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain
| | - Rosa García-Marrero
- Medical Oncology Department, Hospital Universitario de Canarias, Carretera Ofra S/N, 38320 San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
| | - Francisco Zambrana
- Medical Oncology Department, Hospital Universitario Infanta Sofía, Paseo de Europa, 34, 28703 San Sebastián de los Reyes, Madrid, Spain
| | - Aranzazu González-Del Alba
- Medical Oncology Department, Hospital Universitari Son Espases, Carretera de Valldemossa, 79, 07120 Palma, Spain
| | - Martin Lazaro-Quintela
- Medical Oncology Department, Hospital Álvaro Cunqueiro, Estrada de Clara Campoamor, 341, 36213 Vigo, Spain
| | - Daniel Castellano
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Av. de Córdoba, s/n, 28041 Madrid, Spain
| | - Isabel Chirivella
- Medical Oncology Department, Hospital Clínico Universitario de Valencia, Av. de Blasco Ibáñez, 17, 46010 Valencia, Spain
| | - Urbano Anido
- Medical Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain
| | - Antonio Viana
- Medical Oncology Department, Hospital Nuestra Señora del Prado, Carretera de Madrid Km. 114, 45600 Talavera de la Reina, Toledo, Spain
| | - Arancha García
- TFS Trial Form Support S.L., Passeig de Gràcia, 11, 08007 Barcelona, Spain
| | - Miguel Sotelo
- Medical Oncology Department, Hospital Universitario Infanta Cristina, Av. 9 de Junio, 2, 28981 Parla, Madrid, Spain
| | - María Garrido Arévalo
- Medical Oncology Department, Hospital Universitario Severo Ochoa, Av. de Orellana, s/n, 28911 Leganés, Madrid, Spain
| | - Jesús García-Donas
- Medical Oncology Department, Hospital Universitario Clara Campal, Calle de Oña, 10, 28050 Madrid, Spain
| | - Carolina Hernández
- Medical Oncology Department, Hospital Universitario Nuestra Señora de la Candelaria, Ctra. Gral. del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain
| | | | - Julia Llinares
- Pfizer S.L.U. Avenida de Europa, 20, 28108, Madrid, Spain
| | - Miguel A Climent
- Medical Oncology Department, Instituto Valenciano De Oncología, Carrer del Professor Beltrán Báguena, 8, 46009 Valencia, Spain
| |
Collapse
|
11
|
Bonet M, Vázquez S, García E, Visus M, Jové D, Ripol O, Solé C, Gutiérrez L, Morales-Rull JL, Montero Á, Algara M, Arenas M, Mira M. Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience. Clin Transl Oncol 2021; 23:2344-2349. [PMID: 34013493 PMCID: PMC8133050 DOI: 10.1007/s12094-021-02634-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Accepted: 04/29/2021] [Indexed: 12/19/2022]
Abstract
Background The use of low dose radiotherapy (LD-RT) for the treatment of COVID-19 pneumonia is supported by biological rationale for its immunomodulatory effect. Some institutions have started to treat these patients showing encouraging results. To shorten procedure times is crucial for the comfort of symptomatic patients receiving respiratory support and to optimize institutional facilities. Patients and methods At our institution, LD-RT is offered to hospitalized patients with COVID-19 pneumonia and signs of early cytokine-released syndrome on behalf of a multicenter study. We designed a coordinated process flow starting from the patient transfer to the simulation CT-scan (first-step), to the end of the LD-RT treatment (last step). The times spent on each step of the process flow were evaluated. Results Mean age of treated patients was 83 (72–91) years-old. The timing parameters of the first 10 consecutive patients were analyzed. Except for the first (dummy run), patients were managed from the first to the last step in a median of 38 min (25–58, SD 10.67). The most time-consuming sub-process was the contouring of the treatment volumes and dosimetry. Conclusions LD-RT is not only an encouraging option for COVID-19 pneumonia patients, but a convenient and feasible procedure if performed in a coordinated way by reducing procedure times.
Collapse
Affiliation(s)
- M Bonet
- Radiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain.
| | - S Vázquez
- Radiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain
| | - E García
- Radiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain
- IRBLleida (Institut de Recerca Biomèdica de Lleida. Fundació Doctor Pifarré), Lleida, Spain
| | - M Visus
- Radiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - D Jové
- Radiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - O Ripol
- Radiation Physics and Radioprotection Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - C Solé
- Internal Medicine Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - L Gutiérrez
- Internal Medicine Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - J L Morales-Rull
- IRBLleida (Institut de Recerca Biomèdica de Lleida. Fundació Doctor Pifarré), Lleida, Spain
- Internal Medicine Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - Á Montero
- Radiation Oncology Department, Hospital Universitario HM Sanchinarro, Madrid, Spain
| | - M Algara
- Radiation Oncology Department, Parc de Salut Mar, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - M Arenas
- Radiation Oncology Department, Hospital Universitari Sant Joan de Reus, Universitat Rovira I VIrgili, Reus, Spain
| | - M Mira
- Radiation Oncology Department, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain
- IRBLleida (Institut de Recerca Biomèdica de Lleida. Fundació Doctor Pifarré), Lleida, Spain
| |
Collapse
|
12
|
Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO Open 2021; 6:100090. [PMID: 33740735 PMCID: PMC7980066 DOI: 10.1016/j.esmoop.2021.100090] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 01/29/2021] [Accepted: 02/21/2021] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Few studies have investigated the safety and efficacy of anti-PD-(L)1 antibodies in metastatic urothelial carcinoma (mUC) in daily clinical practice. Knowledge about the influence of baseline clinical and analytical factors on therapy outcomes is scarce. PATIENTS AND METHODS We conducted a multicenter retrospective study involving 119 previously treated or untreated mUC patients under anti-PD-(L)1 therapy in a real-world scenario. The objectives of this study were to confirm the safety and efficacy of anti-PD-(L)1 monotherapy and to identify pretreatment factors influencing therapy outcomes. In addition, an independent prognostic model for overall survival (OS) was developed and internally validated. RESULTS Median OS was 7.8 months [95% confidence interval (CI), 5.4-10.4], median progression-free survival (PFS) was 2.80 months (95% CI, 2.4-3.4), disease control rate (DCR) was 40% (95% CI, 31-49), and overall response rate (ORR) was 24% (95% CI, 15-31). Presence of peritoneal metastases was associated with poor OS [hazard ratio (HR) = 2.40, 95% CI, 1.08-5.33; P = 0.03]. Use of proton-pump inhibitors (PPI) was associated with poor OS (HR = 1.83, 95% CI, 1.11-3.02; P = 0.02) and PFS (HR = 1.94, 95% CI, 1.22-3.09; P = 0.005), and lower DCR (OR = 0.38, 95% CI, 0.17-0.89; P = 0.03) and ORR (OR = 0.18, 95% CI, 0.02-1.60; P = 0.002). The three risk category prognostic model developed included Eastern Cooperative Oncology Group performance status, PPI use, albumin level, presence of liver metastases, and presence of peritoneal metastases variables and was associated with higher risk of death (HR = 3.00, 95% CI, 1.97-4.56; P = 0.0001). CONCLUSIONS This study confirms anti-PD-(L)1 monotherapy as a safe and effective treatment option in daily clinical practice for mUC patients. It also describes the presence of peritoneal metastases as an independent prognostic factor for OS and underlines the association between PPI use and worse therapeutic outcomes. Finally, it proposes a new easy-to-use risk-assessment model for OS prediction.
Collapse
Affiliation(s)
- J Ruiz-Bañobre
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), CIBERONC, Santiago de Compostela, Spain.
| | - A Molina-Díaz
- Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - O Fernández-Calvo
- Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - N Fernández-Núñez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - A Medina-Colmenero
- Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain
| | - L Santomé
- Medical Oncology Department, Hospital Povisa, Vigo, Spain
| | - M Lázaro-Quintela
- Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | - M Mateos-González
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), CIBERONC, Santiago de Compostela, Spain
| | - N García-Cid
- Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain
| | - R López-López
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), CIBERONC, Santiago de Compostela, Spain
| | - S Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - U Anido-Herranz
- Medical Oncology Department, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), Santiago de Compostela, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), CIBERONC, Santiago de Compostela, Spain
| |
Collapse
|
13
|
Provencio M, Majem M, Guirado M, Massuti B, de Las Peñas R, Ortega AL, Dómine M, Marsé R, Sala MÁ, Paredes A, Morán T, Vázquez S, Coves J, Larriba JLG, Sánchez JM, Vicente D, Farré N, Fornos LF, Zapata I, Franco F, Serna-Blasco R, Romero A, Isla D. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer 2021; 153:25-34. [PMID: 33453470 DOI: 10.1016/j.lungcan.2021.01.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 12/14/2020] [Accepted: 01/02/2021] [Indexed: 12/20/2022]
Abstract
BACKGROUND Little progress has been achieved in non-small cell lung cancer (NSCLC) patients with unresectable stage III disease and new drug schemes are warranted. MATERIAL AND METHODS In this open-label, single-arm, phase II trial 65 treatment-naïve stage III NSCLC deemed surgically unresectable by a multidisciplinary team were treated with 2 cycles of induction cisplatin at 80 mg/m2 every 21 days plus metronomic oral vinorelbine at 50 mg/day every Monday, Wednesday and Friday. During the concomitant treatment with thoracic radiotherapy cisplatin was administered in the same manner but oral vinorelbine was reduced to 30 mg/day. The objective was to administer a total radiotherapy dose of 66 Gy in 33 daily fractions of 2 Gy. The primary endpoint was progression-free survival (PFS). Correlation between circulating tumor DNA (ctDNA) levels and survival was also evaluated. RESULTS Fifty-five (78.5 %) patients completed treatment. Overall response rate, by RECIST criteria, was 66.2 %. Four (6.2 %) patients had complete response, 39 (60.0 %) partial response and 12 (18.5 %) stable disease. Seven patients (10.8 %) had progressive disease during the induction period. Median follow-up was 29.1 months (m), median PFS was 11.5 m (95 %CI: 9.6-15.4). PFS at 12 m in the intention-to-treat (ITT) population was 47.8 % (95 %CI: 35.1-59.4 %) and median OS was 35.6 m (95 %CI: 24.4-46.8). Grade ≥3 treatment-related adverse events occurred in 14 (21.5 %) patients during induction and in 13 (24.5 %) patients during concomitant treatment with esophagitis occurring in 3% and pneumonitis in 1.5 % of the patients. Patients with undetectable ctDNA after 3 m follow-up had median PFS and OS of 18.1 m (95 %CI: 8.8-NR) and not reached (NR) (95 %CI: 11.3-NR), respectively, compared with 8.0 m (95 %CI: 2.7-NR) and 24.7 m (95 %CI: 5.7-NR) for patients who remained ctDNA positive at that time point. CONCLUSIONS Metronomic oral vinorelbine and cisplatin obtains similar efficacy results with significantly lower toxicity than the same chemotherapy at standard doses. ctDNA can identify populations with particularly good prognosis.
Collapse
Affiliation(s)
- Mariano Provencio
- Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain.
| | - Margarita Majem
- Medical Oncology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
| | - María Guirado
- Medical Oncology, Hospital General Universitario de Elche, Elche, Spain.
| | - Bartomeu Massuti
- Medical Oncology, Hospital General Universitario de Alicante, Alicante, Spain.
| | - Ramón de Las Peñas
- Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
| | | | - Manuel Dómine
- Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, IIS-FJD, Madrid, Spain.
| | - Raquel Marsé
- Medical Oncology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
| | | | - Alfredo Paredes
- Medical Oncology, Hospital Universitario Donostia, San Sebastián, Spain.
| | - Teresa Morán
- Medical Oncology, Catalan Institute of Oncology-Badalona, Hospital Universitari Germans Trias i Pujol, Badalona-Applied Research Group in Oncology, Institut Germans Trias i Pujol, Department of Medicine, Universitat Autònoma de Barcelona, Badalona, Spain.
| | - Sergio Vázquez
- Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
| | - Juan Coves
- Medical Oncology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain.
| | | | | | - David Vicente
- Medical Oncology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain.
| | - Núria Farré
- Radiation Oncology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain.
| | - Luis Fernández Fornos
- Radiotherapic Oncology, Hospital General Universitario de Alicante, Alicante, Spain.
| | - Irma Zapata
- Radiation Oncology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
| | - Fabio Franco
- Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain.
| | - Roberto Serna-Blasco
- Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain; Liquid Biopsy Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Spain.
| | - Atocha Romero
- Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Spain; Liquid Biopsy Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Spain.
| | - Dolores Isla
- Medical Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, IIS Aragón, Spain.
| |
Collapse
|
14
|
Khalaf D, Aragón I, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch D, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco M, Zulfiqar M, Gleave M, Wyatt A, Olmos D, Chi K, Castro E, Almagro E, Arranz J, Billalabeitia E, Borrega P, Castro E, Contreras J, Domenech M, Escribano R, Fernández-Parra E, Gallardo E, García-Carbonero I, García R, Garde J, González del Alba A, González B, Hernández A, Hernando S, Jiménez P, Laínez N, Lorente D, Luque R, Martínez E, Medina A, Méndez-Vidal M, Montesa A, Morales R, Olmos David, Pérez-Gracia J, Pérez-Valderrama B, Pinto Á, Piulats J, Puente J, Querol R, Rodríguez-Vida A, Romero-Laorden N, Sáez M, Vázquez S, Vélez E, Villa-Guzmán J, Villatoro R, Zambrana C. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann Oncol 2020; 31:1186-1197. [DOI: 10.1016/j.annonc.2020.06.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 05/15/2020] [Accepted: 06/03/2020] [Indexed: 12/22/2022] Open
|
15
|
Font A, Luque R, Villa JC, Domenech M, Vázquez S, Gallardo E, Virizuela JA, Beato C, Morales-Barrera R, Gelabert A, Maciá S, Puente J, Rubio G, Maldonado X, Perez-Valderrama B, Pinto A, Fernández Calvo O, Grande E, Garde-Noguera J, Fernández-Parra E, Arranz JÁ. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Target Oncol 2020; 14:15-32. [PMID: 30694442 DOI: 10.1007/s11523-019-00619-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Bladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including histology, stage, patient status, and possible comorbidities. Here we review recent findings on the treatment of muscle-invasive bladder carcinoma, advanced urothelial carcinoma, upper tract urothelial carcinoma, non-urothelial carcinoma, and urologic complications arising from the disease or treatment. In addition, we present the recommendations of the Spanish Oncology Genitourinary Group for the treatment of these diseases, based on a focused analysis of clinical management and the potential of current research, including recent findings on the potential benefit of immunotherapy. In recent years, whole-genome approaches have provided new predictive biomarkers and promising molecular targets that could lead to precision medicine in bladder cancer. Moreover, the involvement of other specialists in addition to urologists will ensure not only appropriate therapeutic decisions but also adequate follow-up for response evaluation and management of complications. It is crucial, however, to apply recent molecular findings and implement clinical guidelines as soon as possible in order to maximize therapeutic gains and improve patient prognosis.
Collapse
Affiliation(s)
- Albert Font
- Medical Oncology Service, B-ARGO Group, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona, Spain.
| | - Raquel Luque
- Medical Oncology Service, H.U. Virgen de las Nieves, Granada, Spain
| | - José Carlos Villa
- Medical Oncology Service, Hospital General Universitario Ciudad Real, Ciudad Real, Spain
| | - Montse Domenech
- Medical Oncology Service, Hospital Fundació Althaia, Manresa, Spain
| | - Sergio Vázquez
- Medical Oncology Service, Hospital Universitario Lucus Augusti, EOXI de Lugo, Cervo e Monforte, Spain
| | - Enrique Gallardo
- Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain
| | | | - Carmen Beato
- Medical Oncology Service, Hospital Virgen de la Macarena, Seville, Spain
| | - Rafael Morales-Barrera
- Medical Oncology Service, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - Sonia Maciá
- Medical Oncology Department, CRO Pivotal, Madrid, Spain
| | - Javier Puente
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain
| | - Gustavo Rubio
- Medical Oncology Service, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain
| | - Xavier Maldonado
- Radiation Oncology Service, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | | | - Alvaro Pinto
- Medical Oncology Service, Hospital Universitario La Paz, Madrid, Spain
| | | | - Enrique Grande
- Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| | | | - Eva Fernández-Parra
- Medical Oncology Service, Hospital Universitario Nuestra Señora de Valme, Seville, Spain
| | - José Ángel Arranz
- Medical Oncology Service, Hospital General Universitario Gregorio Marañon, Madrid, Spain
| |
Collapse
|
16
|
Ruiz-Bañobre J, Areses-Manrique MC, Mosquera-Martínez J, Cortegoso A, Afonso-Afonso FJ, de Dios-Álvarez N, Fernández-Núñez N, Azpitarte-Raposeiras C, Amenedo M, Santomé L, Fírvida-Pérez JL, García-Campelo R, García-González J, Casal-Rubio J, Vázquez S. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res 2019; 8:1078-1085. [PMID: 32010585 DOI: 10.21037/tlcr.2019.11.07] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12-4.60; P<0.0001] and multivariate (HR =3.67, 95% CI, 1.96-6.86; P<0.0001) analyses. Worse LIPI was associated with shorter PFS (HR =1.45, 95% CI, 1.05-2.03; P=0.03), but this correlation did not reach statistical significance in multivariate analysis (HR =1.49, 95% CI, 0.94-2.38; P=0.09). Worse LIPI was associated with lower DCR in univariate [odds ratio (OR) =0.41, 95% CI, 0.24-0.70; P=0.001] and multivariate (OR =0.44, 95% CI, 0.25-0.78; P=0.005) analyses. This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond.
Collapse
Affiliation(s)
- Juan Ruiz-Bañobre
- Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.,Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain
| | | | | | - Alexandra Cortegoso
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.,Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Noemí de Dios-Álvarez
- Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | | | | | - Margarita Amenedo
- Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain
| | - Lucía Santomé
- Medical Oncology Department, Hospital Povisa, Vigo, Spain
| | | | - Rosario García-Campelo
- Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - Jorge García-González
- Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.,Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Joaquín Casal-Rubio
- Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain
| | - Sergio Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| |
Collapse
|
17
|
Martinez Trufero J, Mesia Nin R, Ortega Izquierdo M, Lozano A, Cirauqui Cirauqui B, Rubió Casadevall J, Taberna Sanz M, Pastor Borgoñon M, Lambea Sorrosal J, Iglesias L, Vázquez S, del Barco Morillo E, Perez Segura P, Lopez Pousa A, Ponce J, Cruz-Hernández J. Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz252.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Falo C, Fernández S, Garrigós E, Casado ACV, Vázquez S, Stradella A, Recalde S, Pla M, Campos M, Gumà A, Ortega R, Petit A, Soler T, Perez J, Fernandez E, Bergamino M, Simon SP, Gil M, Ponce J, Tejedor AG. Residual cancer burden as a prognostic factor in a large series of neoadjuvant chemotherapy. Subgroup analysis per molecular surrogated subtypes. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Puente J, González-Del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez Á, Cuevas Sanz JM, Muñoz Del Toro JR, Useros Rodríguez E, García García-Porrero Á, Vázquez S. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer 2019; 19:766. [PMID: 31382926 PMCID: PMC6683519 DOI: 10.1186/s12885-019-5974-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 07/23/2019] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the treatments most frequently administered. METHODS Observational, prospective study conducted in patients with histologically or cytologically confirmed prostate adenocarcinoma; documented metastatic castration-resistant disease; progression after first-line, docetaxel-based chemotherapy with or without other agents. RESULTS Of the 150 patients recruited into the study, 100 patients were prescribed abiraterone acetate plus prednisone (AAP), 44 patients received cabazitaxel plus prednisone (CP), and 6 patients received other treatments. Age (odds ratio [OR] 1.06, 95% [confidence interval] CI 1.01 to 1.11) and not elevated lactate dehydrogenase (LDH) levels (OR 0.33, 95% CI 0.14 to 0.76) were independently associated with the administration of AAP. Treatment with AAP was associated with significantly longer clinical/radiographic progression-free survival (hazard ratio [HR] 0.57, 95% CI 0.38 to 0.85) and overall survival (OS; HR 0.40, 95% CI 0.21 to 0.76) compared to CP, while no significant differences between the treatments were found regarding biochemical progression-free survival (PFS; HR 0.78 [95% CI 0.49 to 1.24]). However, in a post-hoc Cox regression analysis adjusted for potential confounders there were not differences between AAP and CP in any of the time-to-event outcomes, including overall survival. We observed no new safety signals related to either regimen. CONCLUSION Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen. When controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials.
Collapse
Affiliation(s)
- Javier Puente
- Medical Oncology, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, C/Profesor Martín Lagos, s/n 28040, Madrid, Spain.
| | | | | | - María José Méndez-Vidal
- Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC). Reina Sofía Hospital. University of Córdoba, Cordoba, Spain
| | - Alvaro Pinto
- Medical Oncology, University Hospital La Paz - IdiPAZ, Madrid, Spain
| | - Ángel Rodríguez
- Medical Oncology, Hospital Universitario de León, León, Spain
| | | | | | | | | | - Sergio Vázquez
- Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain
| |
Collapse
|
20
|
Braeckman U, Pasotti F, Vázquez S, Zacher K, Hoffmann R, Elvert M, Marchant H, Buckner C, Quartino ML, Mác Cormack W, Soetaert K, Wenzhöfer F, Vanreusel A. Degradation of macroalgal detritus in shallow coastal Antarctic sediments. Limnol Oceanogr 2019; 64:1423-1441. [PMID: 31598006 PMCID: PMC6774326 DOI: 10.1002/lno.11125] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Revised: 10/31/2018] [Accepted: 12/21/2018] [Indexed: 05/22/2023]
Abstract
Glaciers along the western Antarctic Peninsula are retreating at unprecedented rates, opening up sublittoral rocky substrate for colonization by marine organisms such as macroalgae. When macroalgae are physically detached due to storms or erosion, their fragments can accumulate in seabed hollows, where they can be grazed upon by herbivores or be degraded microbially or be sequestered. To understand the fate of the increasing amount of macroalgal detritus in Antarctic shallow subtidal sediments, a mesocosm experiment was conducted to track 13C- and 15N-labeled macroalgal detritus into the benthic bacterial, meiofaunal, and macrofaunal biomass and respiration of sediments from Potter Cove (King George Island). We compared the degradation pathways of two macroalgae species: one considered palatable for herbivores (the red algae Palmaria decipiens) and other considered nonpalatable for herbivores (the brown algae Desmarestia anceps). The carbon from Palmaria was recycled at a higher rate than that of Desmarestia, with herbivores such as amphipods playing a stronger role in the early degradation process of the Palmaria fragments and the microbial community taking over at a later stage. In contrast, Desmarestia was more buried in the subsurface sediments, stimulating subsurface bacterial degradation. Macrofauna probably relied indirectly on Desmarestia carbon, recycled by bacteria and microphytobenthos. The efficient cycling of the nutrients and carbon from the macroalgae supports a positive feedback loop among bacteria, microphytobenthos, and meiofaunal and macrofaunal grazers, resulting in longer term retention of macroalgal nutrients in the sediment, hence creating a food bank for the benthos.
Collapse
Affiliation(s)
- U. Braeckman
- Marine Biology Research GroupGhent UniversityGhentBelgium
- HGF‐MPG Group for Deep Sea Ecology and Technology, Alfred Wegener InstituteHelmholtz Center for Polar and Marine Research, Bremerhaven and Max Planck Institute for Marine MicrobiologyBremenGermany
| | - F. Pasotti
- Marine Biology Research GroupGhent UniversityGhentBelgium
| | - S. Vázquez
- Cátedra de Biotecnología, Facultad de Farmacia y BioquímicaUniversidad de Buenos Aires, NANOBIOTEC UBA‐CONICETBuenos AiresArgentina
| | - K. Zacher
- Functional Ecology, Alfred Wegener InstituteHelmholtz Center for Polar and Marine ResearchBremerhavenGermany
| | - R. Hoffmann
- HGF‐MPG Group for Deep Sea Ecology and Technology, Alfred Wegener InstituteHelmholtz Center for Polar and Marine Research, Bremerhaven and Max Planck Institute for Marine MicrobiologyBremenGermany
| | - M. Elvert
- MARUM Center for Marine Environmental Sciences and Department of GeosciencesUniversity of BremenBremenGermany
| | - H. Marchant
- Biogeochemistry GroupMax Planck Institute for Marine MicrobiologyBremenGermany
| | - C. Buckner
- Biogeochemistry GroupMax Planck Institute for Marine MicrobiologyBremenGermany
| | - M. L. Quartino
- Instituto Antártico Argentino, Coastal Biology DepartmentBuenos AiresArgentina
- Museo Argentino de Ciencias Naturales Bernardino RivadaviaBuenos AiresArgentina
| | - W. Mác Cormack
- Cátedra de Biotecnología, Facultad de Farmacia y BioquímicaUniversidad de Buenos Aires, NANOBIOTEC UBA‐CONICETBuenos AiresArgentina
- Instituto Antártico Argentino, Coastal Biology DepartmentBuenos AiresArgentina
| | - K. Soetaert
- NIOZ Yerseke, Estuarine and Delta Studies and Utrecht UniversityThe Netherlands
| | - F. Wenzhöfer
- HGF‐MPG Group for Deep Sea Ecology and Technology, Alfred Wegener InstituteHelmholtz Center for Polar and Marine Research, Bremerhaven and Max Planck Institute for Marine MicrobiologyBremenGermany
| | - A. Vanreusel
- Marine Biology Research GroupGhent UniversityGhentBelgium
| |
Collapse
|
21
|
Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist 2019; 24:491-497. [PMID: 30867244 DOI: 10.1634/theoncologist.2018-0787] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 02/04/2019] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Real-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). SUBJECTS, MATERIALS, AND METHODS Patients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30 days of enrollment were eligible. Primary objectives included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), relative dose intensity (RDI) and its effect on treatment outcomes, change in health-related quality of life (HRQoL), and safety. We also compared characteristics and outcomes of clinical-trial-eligible (CTE) patients, defined using COMPARZ trial eligibility criteria, with those of non-clinical-trial-eligible (NCTE) patients. Secondary study objectives were to evaluate clinical efficacy, safety, and RDI in patient subgroups. RESULTS Six hundred fifty-seven patients were enrolled and received ≥1 dose of pazopanib. Median PFS and OS were 10.3 months (95% confidence interval [CI], 9.2-12.0) and 29.9 months (95% CI, 24.7 to not reached), respectively, and the ORR was 30.3%. HRQoL showed no or little deterioration over time. Treatment-related serious adverse events (AEs) and AEs of special interest occurred in 64 (9.7%), and 399 (60.7%) patients, respectively. More patients were classified NCTE than CTE (85.2% vs. 14.8%). Efficacy of pazopanib was similar between the two groups. CONCLUSION PRINCIPAL confirms the efficacy and safety of pazopanib in patients with advanced/metastatic RCC in a real-world clinical setting. IMPLICATIONS FOR PRACTICE PRINCIPAL is the largest (n = 657) prospective, observational study of pazopanib in patients with advanced/metastatic renal cell carcinoma, to the authors' knowledge. Consistent with clinical trial results that often contain specific patient types, the PRINCIPAL study demonstrated that the effectiveness and safety of pazopanib is similarly safe and effective in patients with advanced kidney cancer in a real-world clinical setting. The PRINCIPAL study showed that patients with advanced kidney cancer who are treated with first-line pazopanib generally do not show disease progression for approximately 10 months and generally survive for nearly 30 months.
Collapse
Affiliation(s)
| | - Aristotelis Bamias
- National and Kapodistrian University of Athens Alexandra Hospital, Athens, Greece
| | | | - Robert Hawkins
- The Christie Hospital and University of Manchester, Manchester, United Kingdom
| | | | | | - Narayanan Srihari
- Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, United Kingdom
| | | | - Petri Bono
- Helsinki University Hospital and University of Helsinki, Helsinki, Finland
| | | | - Yulia Hirschberg
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Luca Dezzani
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Qasim Ahmad
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Eric Jonasch
- The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| |
Collapse
|
22
|
Lozano R, Castro E, Piulats JM, Medina A, Guzman JCV, Garcia Carbonero I, Villatoro R, Arranz JA, Perez-Gracia JL, Garde J, Gonzalez del Alba A, Montesa A, Luque R, Borrega P, Vázquez S, Martinez E, Gonzalez Gragera B, Romero-Laorden N, Olmos D, Lorente D. Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.264] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
264 Background: Abiraterone (Abi), enzalutamide (Enza) and docetaxel (Doc) are all valid first-line (1L) mCRPC treatment options. Evidence suggests a degree of cross-resistance between agents, which may impact the efficacy of subsequent lines of therapy. Evidence on the optimal treatment sequence is lacking. Methods: We evaluated the outcome of patients (pts) treated with 1L Doc, Abi or Enza in the prospective PROREPAIR-B cohort study. We assessed the impact of 1L treatment option (Doc vs Abi/Enza) on overall survival (OS), progression-free survival (PFS) to 1L-therapy (PCWG2) and PFS2 (time from initiation of 1L-therapy to progression on second-line [2L] therapy). Uni- (UV) and multivariable (MV) cox-regression models were used. MV model covariates included age (≥75 years), local therapy, Gleason Score, metastases at diagnosis, visceral metastases, ALP (≥ULN), LDH (≥ULN), haemoglobin (≤LNL), albumin (≤LNL) and ECOG PS. Results: 406 pts received 1L-Doce (N=188) or Abi/Enza (N=218). Pts receiving Doc were younger (p=0.002), had higher rates of visceral metastases (17.6 vs 8.7%; p=0.008), ALP (52.1% vs 40.4%; p=0.018), LDH (48.1% vs 31.2%; p<0.001) and lower Hb (7.4 vs 2.8%; p=0.029) and albumin (11.3 vs 4.6%). PFS was higher in pts receiving 1L-Abi/Enza (10.8 vs 8.3 months; HR:0.5; p<0.001). Pts receiving 1L Abi/Enza had higher rates of radiographic progression (88.4 vs 80%; p=0.032). 123/188 pts treated with 1L-Doc received 2L-Abi/Enza: 30 received other 2L and 35 had not started 2L. 111/216 pts treated with 1L-Abi/Enza received 2L-Doc, 26 were started on other 2L and 79 had not initiated 2L. A significant difference between pts treated with initial Abi/Enza vs Doc was observed in PFS2 (20.6 vs 16.6m; HR:0.78; p=0.006) but not OS (31.3 vs 29.9 m; HR:1.05; p=0.725). Choice of first-line agent was not associated with OS in the MV model. Conclusions: Despite longer PFS to 1L and PFS2 in pts treated with initial Abi/Enza, no differences in OS were observed between treatment sequences starting with Doc vs Abi/Enza. Pts treated with 1L-Doc had worse baseline prognostic features. Molecular stratification may enable biomarker-driven patient selection to optimize benefit in pts. (NCT03075735).
Collapse
Affiliation(s)
- Rebeca Lozano
- Spanish National Cancer Research Centre, Madrid, Spain
| | - Elena Castro
- Spanish National Cancer Research Centre, Madrid, Spain
| | | | - Ana Medina
- Centro Oncologico de Galicia, La Coruna, Spain
| | | | | | | | | | | | | | - Aranzazu Gonzalez del Alba
- Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, Palma De Mallorca, Spain
| | - A. Montesa
- CNIO-IBIMA Genitorurinary Cancer Clinical Research Unit, Hospitales Universitarios Virgen de la Victoria and Regional de Málaga, Malaga, Spain
| | - Raquel Luque
- Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | | | | | | | | | - David Olmos
- CNIO-IBIMA Genitourinary Cancer Research Unit, Malaga, Spain
| | - David Lorente
- MEdical Oncology Department, Hospital Provincial de Castellón, Castellón De La Plana, Spain
| |
Collapse
|
23
|
Ferrer M, Dorcas J, Quiroga V, Margelí M, del Barco S, Stradella A, Petit A, Falo C, Viñas G, Romeo M, Villanueva R, Cirauqui B, Vázquez S, Fernández A, Recalde S, Vethencourt A, Soler T, Pérez-Martín X, Gil-Gil M. Abstract P5-15-09: Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-15-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Benefit from adjuvant chemotherapy (CT) is doubtful in a high percentage of patients with early breast cancer. The 21-gene recurrence-score (RS) assay (Oncotype DX, Genomic Health) is one gene-expression assay that provide prognostic and predictive information in hormone-receptor (RH) positive breast cancer. The results of the TAILORx study have confirmed that the majority of patients with tumors RH + and HER2 negative can avoid CT without increasing their risk of relapse. From 2012 to 2015 we used Mammaprint (MMP), in our institution and 60% of cases could avoided CT (communicated in SABCS 2015). Since 2017 we use RS for this purpose.
Primary Objective
To analyze the impact of using RS to change the indication of adjuvant CT.
Secondary Objectives
To analyze the association between different clinical pathological factors and the RS value, and calculate the difference between the cost of all RS test and the cost in direct expense of the treatment with CT of all patients who could avoid it thanks to the RS
Material and methods
We analyzed all RS test performed in the three ICO centers during 2017. We sent 112 tumor samples; in 2 samples adequated RNA for RS was not obtained. We compared the adjuvant treatment initially planned according to institutional treatment protocol with the treatment given after RS. We compared the direct economic costs of CT with the costs of the diagnostic test, and performed a logistic regression analysis of some pathological factors and RS value.
Results
The RS could be determined in 110 of 112 cases, in which there was indication of adjuvant CT. Only 14 patients received CT (12,72%) with the RS value, so CT was avoided in 96 patients (87,28%).
The clinical-pathological characteristics of the series are summarized in the table 1. Of the risk factors analyzed, only grade 3 (p 0.001) and PR <20% (p<0.002) showed a statistically significant relationship with a higher probability of RS> 25. No association was found between age, nodal status, tumor diameter, Ki67, Infiltrating Ductal Carcinoma vs neither Infiltrating Lobular Carcinoma nor Lympho-Vascular invasion.
The cost of the genetic studies was 180000€ (1636€ each). The cost of each CT schedule (EC x 4 followed by paclitaxel x 12) was 7214€ and the total cost of 96 cases 692590€. Direct costs savings estimated from the reduction in CT treatment were 512590€
Conclusion: Our series shows that RS avoided unnecessary CT in 87% of cases and was more cost-effective than a previous series with MMP. G3 and RP <20 were the only pathological factors associated with an increased risk of RS> 25.
Table 1.Patients characteristics and clinical-pathological details from the analyzed tumorsPatient characteristicsAge, mean (range)53,76 (19 – 75)≥50y72 (65.5%)<50y38 (34.5%)HistologyInfiltrating ductal carcinoma88 (80%)Infiltrating lobular carcinoma20 (18,2%)Others2 (1,8%)TNMTumor diameter (mm), mean (range)19,25 (1 – 160)pN058 (52,7%)pN1mic21 (19%)pN131 (28,3%)Hormone receptorsRE 2-100%110 (100%)RP <20%22 (20%)RP ≥20%88 (80%)Ki67 median, mean (range)20, 21 (2-75)Lymphovascular invasionyes9 (8%)no101 (92%)Adjuvant treatmentCT14 (12,72%)Hormonotherapy96 (87,28%)
Citation Format: Ferrer M, Dorcas J, Quiroga V, Margelí M, del Barco S, Stradella A, Petit A, Falo C, Viñas G, Romeo M, Villanueva R, Cirauqui B, Vázquez S, Fernández A, Recalde S, Vethencourt A, Soler T, Pérez-Martín X, Gil-Gil M. Impact of oncotype dx genetic signature used in early breast cancer. Clinical and economic analisys of a 110 patient cohort treated in the Catalan Oncologic Institute (ICO), Spain [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-15-09.
Collapse
Affiliation(s)
- M Ferrer
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - J Dorcas
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - V Quiroga
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Margelí
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S del Barco
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Stradella
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Petit
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - C Falo
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - G Viñas
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Romeo
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - R Villanueva
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - B Cirauqui
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S Vázquez
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Fernández
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - S Recalde
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - A Vethencourt
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - T Soler
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - X Pérez-Martín
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Gil-Gil
- Hospital Duran I Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital Josep Trueta. ICO Girona, Girona, Spain; Hospital Germans Trias I Pujol. ICO Badalona, Badalona, Barcelona, Spain; Hospital de Bellvitge. Hospitalet de Llobregat, L'Hospitalet de Llobregat, Barcelona, Spain; Statistical. Clinical Research Unit. Hospital Duran i Reynals. ICO Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
24
|
Bergamino M, Vethencourt A, Stradella A, Recalde S, Fabregat C, Vázquez S, Falo C, Fernández-Ortega A, Villanueva Vazquez R, Ferrer Cardona M, Rubio S, Gil-Gil M. ‘Real world data’ of genomic sequencing for personalised therapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy318.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Marín J, Soler G, Martínez-Villacampa M, Vázquez S, Vivas CS, Margalef NM, Teule A, Salazar R. G8 screening tool for treatment decision-making in elderly colorectal cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Ortega Franco A, Plana M, Braña I, Taberna Sanz M, Oliva Bernal M, Vázquez S, Domenech Vinyolas M, Berenguer G, Vilajosana E, Bergamino M, Baste N, Mesia Nin R. Does hyper-progression exist among head and neck cancer patients treated with immunotherapy? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx374.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
de Azevedo AM, Losada AP, Ferreiro I, Riaza A, Vázquez S, Quiroga MI. New insight on vertebral anomalies in cultured Senegalese sole (Solea senegalensis, Kaup) at early stages of development. J Fish Dis 2017; 40:987-1000. [PMID: 28000918 DOI: 10.1111/jfd.12575] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 10/01/2016] [Accepted: 10/05/2016] [Indexed: 06/06/2023]
Abstract
Senegalese sole (Solea senegalensis, Kaup) is a promising flatfish species in aquaculture. However, skeletal anomalies are still a great concern in sole farming. Investigation of this issue is crucial to improving larval quality and optimizing production. The aim of this study was to thoroughly assess anomalies in the rachis of reared sole at early developmental stages. Sole (n = 507) were sampled at 31 or 32 days after hatching (dah). The specimens were stained with alcian blue and alizarin red and evaluated for the detection of vertebral deformities. Most fish presented 9:34:3 vertebrae in abdominal, caudal and caudal complex regions, respectively. Remarkably, all specimens showed at least one spinal anomaly. Alterations of neural/haemal elements, as well as deformities of hypurals, parhypural and epural, were recurrent. Vertebral body anomalies and/or vertebral column deviations were identified in 52% of the individuals. Vertebral deformations and fusions were common, especially in caudal complex. 'Minor' anomalies were predominant, and some of the detected disorders might be a result of non-/low-pathological processes. These results contribute a new insight into the main skeletal anomalies affecting cultured sole larvae. Further research is required to determine their impact on fish welfare and external appearances at commercial stages.
Collapse
Affiliation(s)
- A M de Azevedo
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, Spain
| | - A P Losada
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, Spain
| | | | - A Riaza
- Stolt Sea Farm, A Coruña, Spain
| | - S Vázquez
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, Spain
| | - M I Quiroga
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, Spain
| |
Collapse
|
28
|
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget 2017; 8:30410-30421. [PMID: 28423742 PMCID: PMC5444752 DOI: 10.18632/oncotarget.16494] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 02/24/2017] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further investigation. PATIENTS AND METHODS Multicenter, observational, retrospective study in patients with clear-cell mRCC treated with sunitinib. Patients were classified in two groups: long-term responders (LR) (progression-free survival (PFS)≥22 months and at least stable disease), and primary refractory (PR) (progressive disease within 3-months of sunitinib onset). Objectives were to compare baseline clinical factors in both populations and to correlate tumor expression of selected signaling pathways components with sunitinib PFS. RESULTS 123 patients were analyzed (97 LR, 26 PR). In the LR cohort, overall response rate was 79% and median duration of best response was 30 months. Median PFS and overall survival were 43.2 (95% confidence intervals[CI]:37.2-49.3) and 63.5 months (95%CI:55.1-71.9), respectively. At baseline PR patients had a significantly lower proportion of nephrectomies, higher lactate dehydrogenase and platelets levels, lower hemoglobin, shorter time to and higher presence of metastases, and increased Fuhrman grade. Higher levels of HEYL, HEY and HES1 were observed in LR, although only HEYL discriminated populations significantly (AUC[ROC]=0.704; cut-off=34.85). Increased levels of hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p were also associated with prolonged survival. No statistical significant associations between hsa-miR-23b or hsa-miR-27b and the expression of c-Met were found. CONCLUSIONS Certain mRCC patients treated with sunitinib achieve extremely long-term responses. Favorable baseline hematology values and longer time to metastasis may predict longer PFS. HEYL, hsa-miR-27b, hsa-miR-23b and hsa-miR-628-5p could be potentially used as biomarkers of sunitinib response.
Collapse
Affiliation(s)
- Javier Puente
- Medical Oncology Department, Instituto de Investigación Biomédica, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - Nuria Laínez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - Marta Dueñas
- Molecular Oncology Unit CIEMAT and Instituto Investigación Biomédica, Hospital Universitario 12 de Octubre, Madrid, Spain
- CIBERONC, Spain
| | | | - Emilio Esteban
- Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Daniel Castellano
- CIBERONC, Spain
- Medical Oncology Department, and Instituto Investigación Biomédica, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Mónica Martinez-Fernández
- Molecular Oncology Unit CIEMAT and Instituto Investigación Biomédica, Hospital Universitario 12 de Octubre, Madrid, Spain
- CIBERONC, Spain
| | | | | | - Luis Antón
- Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain
| | - Luis León
- Promoción e Planificación da Investigación Sanitaria, Axencia de Coñecemento en Saúde, Santiago de Compostela, Spain
| | - Julio Lambea
- Medical Oncology Department, Hospital Clínico de Zaragoza, Zaragoza, Spain
| | | | - Sergio Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - Cristina Suarez
- Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d' Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Xavier Garcia del Muro
- Medical Oncology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain
| | - Enrique Gallardo
- Medical Oncology Department, Hospital Universitari Parc Taulí, Sabadell, Spain
| | - José Pablo Maroto
- Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Luz Samaniego
- Statistical Department, Trial Form Support TFS people, Madrid, Spain
| | | | - Julián Sanz
- Pathology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - Jesús M. Paramio
- Molecular Oncology Unit CIEMAT and Instituto Investigación Biomédica, Hospital Universitario 12 de Octubre, Madrid, Spain
- CIBERONC, Spain
| | | |
Collapse
|
29
|
de Azevedo AM, Losada AP, Barreiro A, Barreiro JD, Ferreiro I, Riaza A, Vázquez S, Quiroga MI. Skeletal anomalies in reared Senegalese sole Solea senegalensis juveniles: a radiographic approach. Dis Aquat Organ 2017; 124:117-129. [PMID: 28425425 DOI: 10.3354/dao03110] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Reared Senegalese sole Solea senegalensis Kaup show a high incidence of vertebral anomalies; however, little is known about its skeletal anomaly profile in the later farming phases. The purpose of this study was to provide a detailed description and quantification of the most common skeletal anomalies in reared Senegalese sole in the juvenile stage by means of computed radiography. A total of 374 Senegalese sole were classified according to the external morphology of the fish as normal or altered and then radiographed in latero-lateral and in dorso-ventral projections. Radiographic evaluation of anomalies focused especially on vertebral body anomalies (VBA) and vertebral column deviations (VCD). The 2 orthogonal projections provided a more complete visualization of the skeleton. Approximately 75% of the individuals showed at least 1 anomaly, while VBA and/or VCD were detected in 48.9% of the specimens. Regarding external morphology, 88% of the fish were categorized as normal, although about 72% of these normal fish displayed abnormalities in radiographies. The most frequent anomalies consisted of deformations of the caudal complex plates (hypurals, parhypural and epural), preurals and caudal vertebrae. Scoliosis was the most prevalent among VCD, affecting the caudal area in almost 15% of the individuals. The anomaly profile at the juvenile stages showed some differences compared to what has been reported previously in earlier stages of development. In light of these results, further investigation into the progression of skeletal anomalies over time and the causative factors at later stages is required.
Collapse
Affiliation(s)
- A M de Azevedo
- Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo 27002, Spain
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Guerrero M, Vázquez S, Ayllón JA, Calvet T, Font-Bardia M, Pons J. Zn(II) and Cd(II) Coordination Dimers Based on Mixed Benzodioxole-Carboxylate and N-Donor Ligands: Synthesis, Characterization, Crystal Structures and Photoluminescence Properties. ChemistrySelect 2017. [DOI: 10.1002/slct.201602017] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Miguel Guerrero
- Departament de Química; Universitat Autònoma de Barcelona; 08193-Bellaterra Barcelona Spain
- Departament de Física; Universitat Autònoma de Barcelona; 08193-Bellaterra Barcelona Spain
| | - Sergio Vázquez
- Departament de Química; Universitat Autònoma de Barcelona; 08193-Bellaterra Barcelona Spain
| | - José A. Ayllón
- Departament de Química; Universitat Autònoma de Barcelona; 08193-Bellaterra Barcelona Spain
| | - Teresa Calvet
- Cristal⋅lografia, Mineralogia i Dipòsits Minerals; Universitat de Barcelona, Martí i Franquès s/n; 08028- Barcelona Spain
| | - Merce Font-Bardia
- Unitat de Difracció de Raig-X; Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB); Universitat de Barcelona; Solé i Sabarís, 1-3 08028- Barcelona Spain
| | - Josefina Pons
- Departament de Química; Universitat Autònoma de Barcelona; 08193-Bellaterra Barcelona Spain
| |
Collapse
|
31
|
Lázaro M, Gallardo E, Doménech M, Pinto Á, González-del-Alba A, Del Alba AG, Puente J, Fernández O, Font A, Lainez N, Vázquez S. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol 2016; 18:1197-1205. [PMID: 27900539 PMCID: PMC5138255 DOI: 10.1007/s12094-016-1584-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Accepted: 11/15/2016] [Indexed: 12/21/2022]
Abstract
The goal of this article is to provide recommendations for the diagnosis and treatment of muscle-invasive and metastatic bladder cancer. The diagnosis of muscle-invasive bladder cancer is made by pathologic evaluation after transurethral resection. Recently, a molecular classification has been proposed. Staging of muscle-invasive bladder cancer must be done by computed tomography scans of the chest, abdomen and pelvis and classified on the basis of UICC system. Radical cystectomy and lymph node dissection are the treatment of choice. In muscle-invasive bladder cancer, neoadjuvant chemotherapy should be recommended in patients with good performance status and no renal function impairment. Although there is insufficient evidence for use of adjuvant chemotherapy, its use must be considered when neoadjuvant therapy had not been administered in high-risk patients. Multimodality bladder-preserving treatment in localized disease is an alternative in selected and compliant patients for whom cystectomy is not considered for clinical or personal reasons. In metastatic disease, the first-line treatment for patients must be based on cisplatin-containing combination. Vinflunine is the only drug approved for use in second line in Europe. Recently, immunotherapy treatment has demonstrated activity in this setting.
Collapse
Affiliation(s)
- M Lázaro
- Medical Oncology Department, Hospital Álvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, Estrada Clara Campoamor, 34136312, Vigo, Spain.
| | - E Gallardo
- Medical Oncology Department, Parc Taulí Sabadell Hospital Universitari, Sabadell, Spain
| | - M Doménech
- Medical Oncology Department, Althaia, Xarxa Assisencial i Universitària de Manresa, Manresa, Spain
| | - Á Pinto
- Medical Oncology Department, Hospital Universitario La Paz-Idipaz, Madrid, Spain
| | | | - A González Del Alba
- Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain
| | - J Puente
- Medical Oncology Department, Hospital Universitario San Carlos, Madrid, Spain
| | - O Fernández
- Complexo Hospitalario Universitario de Ourense, Badalona, Spain
| | - A Font
- Medical Oncology Department, Germans Trias i Pujol University Hospital, Badalona, Spain
| | - N Lainez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - S Vázquez
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| |
Collapse
|
32
|
Vázquez S, Martín A, García M, Español C, Navarro E. Metal uptake of Nerium oleander from aerial and underground organs and its use as a biomonitoring tool for airborne metallic pollution in cities. Environ Sci Pollut Res Int 2016; 23:7582-7594. [PMID: 26732705 DOI: 10.1007/s11356-015-6002-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 12/22/2015] [Indexed: 06/05/2023]
Abstract
The analysis of the airborne particulate matter-PM-incorporated to plant leaves may be informative of the air pollution in the surroundings, allowing their use as biomonitoring tools. Regarding metals, their accumulation in leaves can be the result of both atmospheric incorporation of metallic PM on aboveground plant organs and root uptake of soluble metals. In this study, the use of Nerium oleander leaves as a biomonitoring tool for metallic airborne pollution has been assessed. The metal uptake in N. oleander was assessed as follows: (a) for radicular uptake by irrigation with airborne metals as Pb, Cd, Cr, Ni, As, Ce and Zn (alone and in mixture) and (b) for direct leave exposure to urban PM. Plants showed a high resistance against the toxicity of metals under both single and multiple metal exposures. Except for Zn, the low values of translocation and bioaccumulation factors confirmed the excluder behaviour of N. oleander with respect to the metals provided by the irrigation. For metal uptake from airborne pollution, young plants grown under controlled conditions were deployed during 42 days in locations of the city of Zaragoza (700,000 h, NE Spain), differing in their level of traffic density. Samples of PM2.5 particles and the leaves of N. oleander were simultaneously collected weekly. High correlations in Pb concentrations were found between leaves and PM2.5; in a lesser extent, correlations were also found for Fe, Zn and Ti. Scanning electron microscopy showed the capture of airborne pollution particles in the large and abundant substomatal chambers of N. oleander leaves. Altogether, results indicate that N. Oleander, as a metal resistant plant by metal exclusion, is a suitable candidate as a biomonitoring tool for airborne metal pollution in urban areas.
Collapse
Affiliation(s)
- S Vázquez
- San Jorge University. Campus Universitario Villanueva de Gállego - Autovía A-23, Zaragoza-Huesca Km. 299, Villanueva de Gállego, 50.830, Zaragoza, Spain
- School of Biosciences, University of Nottingham, Sutton Bonington Campus, Leicestershire, Loughborough, LE12 5RD, UK
| | - A Martín
- Pyrenean Institute of Ecology-CSIC, Avda. Montañana 1005, 50.059, Zaragoza, Spain
- San Jorge University. Campus Universitario Villanueva de Gállego - Autovía A-23, Zaragoza-Huesca Km. 299, Villanueva de Gállego, 50.830, Zaragoza, Spain
| | - M García
- Pyrenean Institute of Ecology-CSIC, Avda. Montañana 1005, 50.059, Zaragoza, Spain
- San Jorge University. Campus Universitario Villanueva de Gállego - Autovía A-23, Zaragoza-Huesca Km. 299, Villanueva de Gállego, 50.830, Zaragoza, Spain
| | - C Español
- Pyrenean Institute of Ecology-CSIC, Avda. Montañana 1005, 50.059, Zaragoza, Spain
- San Jorge University. Campus Universitario Villanueva de Gállego - Autovía A-23, Zaragoza-Huesca Km. 299, Villanueva de Gállego, 50.830, Zaragoza, Spain
| | - E Navarro
- Pyrenean Institute of Ecology-CSIC, Avda. Montañana 1005, 50.059, Zaragoza, Spain.
- San Jorge University. Campus Universitario Villanueva de Gállego - Autovía A-23, Zaragoza-Huesca Km. 299, Villanueva de Gállego, 50.830, Zaragoza, Spain.
| |
Collapse
|
33
|
Duran I, Hagen C, Arranz JÁ, Apellaniz-Ruiz M, Pérez-Valderrama B, Sala N, Lainez N, García-Del Muro X, Noguerón E, Climent MÁ, Maroto P, Font A, García-Donas J, Gallardo E, López-Criado P, González Del Alba A, Sáez MI, Vázquez S, Luque R, Rodríguez-Antona C. SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics 2016; 17:463-71. [PMID: 27020167 DOI: 10.2217/pgs.15.186] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM We aimed to identify SNPs associated with cabazitaxel toxicity and response within a Phase II clinical trial using this compound in advanced transitional cell carcinoma after progression to a platinum-based regimen. PATIENTS & METHODS Eleven SNPs in CYP3A4, CYP3A5, CYP2C8, ABCB1 and TUBB1 were genotyped in 45 patients. RESULTS CYP3A5 rs776746 A allele was associated with protection against gastrointestinal toxicity (odds ratio: 0.06, 95% CI: 0.007-0.63, p = 0.018) and with reduced progression-free survival (hazard ratio: 5.1, 95% CI: 1.7-15.1, p = 0.0038, multivariable analysis). ABCB1 SNPs were associated with total number of grade 3-4 toxicity events (p-values of 0.009, 0.041 and 0.043, respectively). CONCLUSION Polymorphisms in CYP3A5 and ABCB1 may define a subset of patients with different cabazitaxel toxicity and efficacy and therefore could be used as markers for treatment optimization.
Collapse
Affiliation(s)
- Ignacio Duran
- Hospital Universitario Virgen del Rocio, Seville, Spain
| | - Carlos Hagen
- Spanish Oncology Genitourinary Group, Madrid, Spain
| | | | - María Apellaniz-Ruiz
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | | | - Nuria Sala
- Instituto Catalan de Oncologia Josep Trueta, Girona, Spain
| | - Nuria Lainez
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | | | - Esther Noguerón
- Complejo Hospitalario Universitario de Albacete, Albacete, Spain
| | | | - Pablo Maroto
- Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
| | - Albert Font
- Instituto Catala de Oncologia, Hospital Universitario Germans Trias y Pujol, Badalona, Spain
| | | | | | | | | | | | | | - Raquel Luque
- Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - Cristina Rodríguez-Antona
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain
| |
Collapse
|
34
|
Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M, Abdulkader I, González-Arenas C, Fachal L, Vega A. EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10). Cancer Manag Res 2016; 8:11-20. [PMID: 26893581 PMCID: PMC4745839 DOI: 10.2147/cmar.s85173] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Purpose This study aimed to assess the incidence of mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients in the Galician region of Spain and the clinical management and outcome of patients carrying EGFR mutations. Patients and methods All newly diagnosed advanced or metastatic NSCLC patients were screened for EGFR mutations in matched tumor samples (tissue or cytology specimens) and serum samples. Results Of 198 patients screened for EGFR mutations in tumor samples, 184 had evaluable data and, of these, 25 (13.6%) had EGFR mutations (84% sensitizing mutations). EGFR mutation was found in serum in 14 (8.1%) patients (of 174 evaluable). Compared to matched tumor tissue, serum EGFR mutation testing specificity and sensitivity were 99% and 52%, respectively. All but two patients received gefitinib. Median progression-free survival and overall survival were 10 (95% confidence interval: 4.8–15.3) months and 17.8 (95% confidence interval: 13.9–21.6) months, respectively, in patients carrying sensitizing mutations. Conclusion The incidence of EGFR mutations in Galicia is consistent with previous data in Spain. Our results also support the feasibility of EGFR testing to guide treatment decision making using tumor tissue or cytology samples, or serum samples if tumor specimens are unavailable. These findings also confirm that first-line gefitinib is an active treatment option in Caucasians with EGFR mutation-positive NSCLC.
Collapse
Affiliation(s)
- Sergio Vázquez
- Medical Oncology Department, Lucus Augusti University Hospital, Lugo, Spain
| | - Joaquín Casal
- Medical Oncology Department, University Hospital Complex of Vigo, Pontevedra, Spain
| | | | - José Luis Fírvida
- Medical Oncology Department, University Hospital Complex of Ourense, Ourense, Spain
| | - Lucía Santomé
- Medical Oncology Department Povisa Hospital, Vigo, Spain
| | - Francisco Barón
- Medical Oncology Department, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain
| | - Martín Lázaro
- Medical Oncology Department, Hospital Complex of Pontevedra, Pontevedra, Spain
| | - Carolina Pena
- Medical Oncology Department, Hospital Complex of Pontevedra, Pontevedra, Spain
| | - Margarita Amenedo
- Medical Oncology Department, Oncology Center of Galicia, A Coruña, Spain
| | - Ihab Abdulkader
- Anatomical Pathology Department, University Hospital Complex of Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Laura Fachal
- Galician Public Foundation of Genomic Medicine-SERGAS, Santiago de Compostela Clinic Hospital, Santiago de Compostela, Spain
| | - Ana Vega
- Galician Public Foundation of Genomic Medicine-SERGAS, Santiago de Compostela Clinic Hospital, Santiago de Compostela, Spain
| |
Collapse
|
35
|
Oliveras A, Sans-Atxer L, Vázquez S. [Is blood pressure control different in women than in men?]. Hipertens Riesgo Vasc 2015; 32:151-8. [PMID: 26486463 DOI: 10.1016/j.hipert.2015.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 08/04/2015] [Indexed: 10/23/2022]
Abstract
Blood pressure (BP) evolves with age; until the 50's it is higher in men than in women, equaling and even then increasing in women. The prevalence of controlled BP appears to be similar between the sexes, but the prevalence of cardiovascular disease is higher in women than in men. The possibility that BP influences the cardiovascular risk differently according to sex must therefore be considered. While some studies suggest no difference exists, others have shown evidence of an increased risk in women with respect to men despite equal BP. In this way, it seems that the measurement of ambulatory BP, but not office BP, would mark the differences in the association between BP-gender and cardiovascular risk. It should therefore be investigated the possibility of a different BP goal for women and men, especially by evaluating ambulatory BP.
Collapse
Affiliation(s)
- A Oliveras
- Unidad de Hipertensión y Riesgo Vascular, Servicio de Nefrología, Hospital Universitari del Mar; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España.
| | - L Sans-Atxer
- Unidad de Hipertensión y Riesgo Vascular, Servicio de Nefrología, Hospital Universitari del Mar; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España
| | - S Vázquez
- Unidad de Hipertensión y Riesgo Vascular, Servicio de Nefrología, Hospital Universitari del Mar; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España
| |
Collapse
|
36
|
Montal R, De Avila L, Taberna M, Oliva M, Rovira A, Cos M, Mañós M, Navarro V, Nogués J, Lozano A, Vázquez S, Mesia R. Residual Neck Disease (Rnd) Management in Squamous-Cell Carcinoma of the Head and Neck (Scchn) Treated with Radiotherapy (Rt) Plus Cetuximab (C). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu340.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Juan O, Sánchez-Hernández A, Vázquez S, Casal J, Firvida JL, Aparisi F, Muñoz J, García-Sánchez J, Gironés R, Lázaro M, Giner V. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res 2014; 34:1959-1966. [PMID: 24692732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
AIM To evaluate the efficacy and toxicities of combination of cisplatin and oral vinorelbine given at full doses concomitantly with radiotherapy for non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Untreated patients with locally advanced inoperable stage IIIA/IIIB NSCLC were eligible for study inclusion. Treatment consisted of four cycles of oral vinorelbine at 60 mg/m(2) on days 1 and 8, and cisplatin at 80 mg/m(2) on day 1 every three weeks plus radiotherapy 66 Gy starting on day 1 of cycle 2 in fractions of 2 Gy/day over 6.5 weeks. RESULTS Forty-eight patients were enrolled. Their characteristics included: median age 61 years; female gender 10%; stage IIIA 46% and IIIB 54%; squamous carcinoma 63%, performance status PS0 42%; PS1 58%. Selected grade 3/4 toxicities were as follows: neutropenia 33%, concomitant febrile neutropenia 14.6%, anemia 12.5%, thrombocytopenia 16.6%, and esophagitis 12.5%. Two treatment-related deaths were reported, both during cycle 1. Radiotherapy was administered to 87.5% of patients; 7.1% of them received less than 60 Gy and 23.8% had delays due to adverse events. The objective response rate was 77.3%, with two complete responses and 32 partial responses. With a median follow-up of 19 months, the median progression-free survival was 12 months, and the 1-year overall survival rate was 72.3%. Median overall survival was 27.8 months, although the 95% confidence interval has not yet been achieved. CONCLUSION Full doses of cisplatin and oral vinorelbine can be administered with concomitant radiotherapy, with good efficacy and an acceptable safety profile for patients with stage IIIA/IIIB NSCLC.
Collapse
Affiliation(s)
- Oscar Juan
- Department of Medical Oncology, La Fe University Hospital, Bulevar Sur s/n. 46026, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Taberna M, Hierro C, Vázquez S, Navarro V, Vilajosana E, Nogués J, Mañós M, Lozano A, Mesía R. Influence of Treatment Received in Long-Surviving Patients of Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2013.11.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
39
|
Russo M, Sevlever G, Vázquez S, Gustafson D, Surace E, Campos J, Martín M, Martineto H, Ventrice F, Guinjoan S, Allegri R. Argentina-ADNI: Preliminary report on CSF biomarkers. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.1181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
De Azevedo A, Losada A, Barreiro A, Barreiro J, Ferreiro I, Riaza A, Vázquez S, Quiroga M. Diagnostic Methods For the Detection Of Vertebral Malformations In Senegal Sole (Solea senegalensis, KAUP 1858) At Different Stages of Development. J Comp Pathol 2013. [DOI: 10.1016/j.jcpa.2012.11.183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Barrientos N, Vázquez S, Domínguez JD. Contact Urticaria Induced by Hydrolyzed Wheat Protein in Cosmetic Cream. Actas Dermo-Sifiliográficas (English Edition) 2012. [DOI: 10.1016/j.adengl.2012.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
42
|
Leon L, Vázquez S, Gracia JM, Casal J, Lazaro M, Firvida JL, Amenedo M, Santome L, Macia S. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opin Pharmacother 2012; 13:1389-96. [PMID: 22630129 DOI: 10.1517/14656566.2012.693165] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). RESEARCH DESIGN AND METHODS Forty-nine patients with stage IIIB plus pleural effusion or stage IV NSCLC were included in a Phase II clinical trial. Treatment consisted of 3-week cycles of bevacizumab (15 mg/kg on day 1), cisplatin (80 mg/m(2) on day 1) and vinorelbine (25 mg/m(2) on days 1 and 8). After 6 cycles, non-progressing patients received bevacizumab maintenance therapy. The primary end point was progression-free survival (PFS), calculated using the Kaplan-Meier method. RESULTS Thirteen (29%) of 45 evaluable patients presented a partial response. PFS and overall survival were 6.0 months (95% confidence interval (CI) 4.5 - 7.5) and 14.7 months (95% CI 8.4 - 21), respectively. Fourteen patients (28%) experienced grade 3 - 4 neutropenia and 7 (14%) experienced febrile neutropenia during the combination treatment. During the maintenance phase, the most frequent grade 3 - 4 adverse event was hypertension. Neither grade 3 - 4 thrombocytopenia nor toxic death was observed. CONCLUSIONS The studied regimen achieved a similar efficacy to other regimens containing platinum doublets. The data provide further evidence that bevacizumab may be used in combination with multiple standard platinum-based doublets in this setting.
Collapse
Affiliation(s)
- Luis Leon
- Complexo Hospitalario Universitario de Santiago, Medical Oncology Department, Travesía da Choupana, s/n, 15706 Santiago de Compostela, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Vázquez S, León L, Fernández O, Lázaro M, Grande E, Aparicio L. Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Ther 2012; 29:202-17. [PMID: 22328304 DOI: 10.1007/s12325-011-0099-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Indexed: 10/14/2022]
Abstract
Tyrosine kinase inhibitors (TKIs) are beneficial for the treatment of renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors (pNETs), and other tumors. The antitumor activity of sunitinib has been based on time-related parameters such as progression-free survival (PFS) and overall survival (OS). Advances in knowledge of the molecular mechanisms and oncogenic processes associated with RCC have enabled the availability of rational targets for pharmacotherapy. Although each small molecule is modeled to block the activity of selected kinase signaling enzymes, it is increasingly evident that many have nontargeted effects (on other kinases) that may cause unexpected complications. The recommended dose for sunitinib in patients with advanced RCC is a 50 mg oral daily dose, with or without food, on a 4/2 week schedule (4 weeks "on" vs. 2 weeks "off") until progression. An alternative continuous 37.5 mg/day dosing schedule has also been evaluated and appears to be well tolerated, allowing the maintenance of the dose density of sunitinib with a similar outcome. The continuous administration schedule provides a constant exposure to the drug, and may prevent potential tumor regrowth and angiogenesis recovery. Most side effects are reversible and should not result in sunitinib discontinuation. In this article, the body of evidence behind the use of sunitinib in metastatic RCC (mRCC) compared to other targeted agents that have recently come into the field is summarized, and the need for correct management of an adverse event profile in order to better optimize available treatment options is underlined.
Collapse
|
44
|
Palencia R, Higuera N, Vázquez S. [Congenital glycosylation disorders: a study of two patients]. An Pediatr (Barc) 2011; 76:153-5. [PMID: 22115835 DOI: 10.1016/j.anpedi.2011.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2011] [Revised: 10/03/2011] [Accepted: 10/04/2011] [Indexed: 12/01/2022] Open
Abstract
BACKGROUND Congenital glycosylation disorders (CGDs) are a group of disorders caused by a defect in glycoprotein synthesis. Clinical manifestations may affect to different organs. AIMS To describe two new patients cases with a CGD in order to make paediatricians aware of this disorder. CLINICAL CASES Two new cases of different age and gender are presented, showing clinical manifestations, and radiological and laboratory findings compatible with CGD. One of the cases was followed up for several years. CONCLUSIONS Glycosylation disorders are a group of conditions to bear in mind when considering the diagnosis of a patient with neurological symptoms of unexplained origin, particularly in those cases that include a delay in psychomotor activity, low muscle tone, epilepsy, and hepatic or coagulation disorders, as well as in patients with cerebellar or olivopontocerebellar atrophy.
Collapse
Affiliation(s)
- R Palencia
- Neuropediatría, Hospital Clínico, Valladolid, España.
| | | | | |
Collapse
|
45
|
Fírvida J, Vázquez S, Casal J, Fernández A, Varela S, Villanueva M, Pérez E, Campos B, Salgado M, Mel J. 9088 POSTER Erlotinib as Frontline Treatment for Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC) and Non-Squamous Histology – Results of a Galician Lung Cancer Group (GGCP044/09 Study) Grupo Galego De Cancro De Pulmon (GGCP). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72400-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
46
|
Vázquez S, Villanueva M, Firvida J, Lázaro M, Campos B, Grande C, Fernandez A, Varela S, Casal J, Perez E. 9085 POSTER Gemcitabine Plus Oral Vinorelbine as Salvage Therapy Treatment for Patients With Advanced Non-small-cell Lung Cancer and Squamous Histology – a Gallclan Lung Cancer Group Study (GGCP042/09) Grupo Galego De Cancro De Pulmon (GGCP). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72397-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Herrera J, Vázquez S, Luna E, Salas L, Nuñez J, Sohn E, Ruiz E. Variant of the anastigmatic telescope with three mirrors for back focal length. Appl Opt 2011; 50:1905-1914. [PMID: 21532673 DOI: 10.1364/ao.50.001905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In this paper, an optical design is presented for an anastigmatic telescope with back focal length corrected with exact ray tracing to eliminate spherical, coma, and astigmatism aberrations. The telescope is formed of three conical mirrors, two of them polished on the same substratum. The optical design is divided into three stages: we began the design obtaining the Gaussian parameters in a first-order solution; posteriorly, were obtained analytically the three mirrors' asphericity in a third-order design. The final design stage consists of the implementation of the Fermat's principle, the Abbe sine condition, and the Coddington equations for the exact correction for the three aforementioned aberrations.
Collapse
Affiliation(s)
- J Herrera
- Universidad Nacional Autonoma de México, Instituto de Astronomía, Observatorio Astronomico Nacional. Apdo. Postal 877, Ensenada, B. C. 22800, Mexico.
| | | | | | | | | | | | | |
Collapse
|
48
|
Fernández A, Vila JJ, Vázquez S, González-Portela C, de la Iglesia M, Lozano M, Toscano E. Self-expanding plastic stents for the treatment of post-operative esophago-jejuno anastomosis leak. A case series study. Rev Esp Enferm Dig 2011; 102:704-10. [PMID: 21198312 DOI: 10.4321/s1130-01082010001200005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
OBJECTIVE Self-expandable plastic stents (SEPS) are increasingly being used for treatment of postoperative esophageal leak. This complication occurs in 4-27% of patients after radical gastrectomy, and has a high mortality rate up to 60%.The aim of this study is to evaluate the efficacy of SEPS (Polyflex®) for treatment of post-operative esophago-jejuno anastomosis leak after radical gastrectomy for gastric cancer. MATERIAL AND METHODS During one year period patients who underwent a radical gastrectomy in our hospital for gastric cancer and developed a postoperative anastomotic leak were prospectively included in the study after signing a consent form, and treated with SEPS placement under endoscopic and fluoroscopic control for leak occlusion. RESULTS Four patients were included (3 men/1 woman). The mean interval between operation and SEPS placement was 16 days (range: 4-34). SEPS deployment was easily performed in all patients with complete occlusion of esophageal lumen in three patients. In the fourth patient we needed to deploy a second coaxial stent to achieve a complete occlusion of the fistula. SEPS migration did not happen in our series. One patient had already developed a mediastinitis by the time we placed the SEPS and he died 3 days later. Extraction of the SEPS was easily performed 4-8 weeks after deployment. CONCLUSION We achieved a complete healing of the anastomotic fistula after radical gastrectomy in 3 out of 4 patients, without major complications related to SEPS. Placement of SEPS is an appealing minimally invasive alternative to surgical repair for patients with postoperative anastomotic leak.
Collapse
Affiliation(s)
- A Fernández
- Gastroenterology Department, POVISA Hospital, C/Salamanca 5, Vigo, Pontevedra, Spain.
| | | | | | | | | | | | | |
Collapse
|
49
|
|
50
|
Sagardoy R, Vázquez S, Florez-Sarasa ID, Albacete A, Ribas-Carbó M, Flexas J, Abadía J, Morales F. Stomatal and mesophyll conductances to CO2 are the main limitations to photosynthesis in sugar beet (Beta vulgaris) plants grown with excess zinc. New Phytol 2010; 187:145-158. [PMID: 20374501 DOI: 10.1111/j.1469-8137.2010.03241.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
*The effects of zinc (Zn) toxicity on photosynthesis and respiration were investigated in sugar beet (Beta vulgaris) plants grown hydroponically with 1.2, 100 and 300 microM Zn. *A photosynthesis limitation analysis was used to assess the stomatal, mesophyll, photochemical and biochemical contributions to the reduced photosynthesis observed under Zn toxicity. *The main limitation to photosynthesis was attributable to stomata, with stomatal conductances decreasing by 76% under Zn excess and stomata being unable to respond to physiological and chemical stimuli. The effects of excess Zn on photochemistry were minor. Scanning electron microscopy showed morphological changes in stomata and mesophyll tissue. Stomatal size and density were smaller, and stomatal slits were sealed in plants grown under high Zn. Moreover, the mesophyll conductance to CO(2) decreased by 48% under Zn excess, despite a marked increase in carbonic anhydrase activity. Respiration, including that through both cytochrome and alternative pathways, was doubled by high Zn. *It can be concluded that, in sugar beet plants grown in the presence of excess Zn, photosynthesis is impaired due to a depletion of CO(2) at the Rubisco carboxylation site, as a consequence of major decreases in stomatal and mesophyll conductances to CO(2).
Collapse
Affiliation(s)
- R Sagardoy
- Department of Plant Nutrition, Aula Dei Experimental Station, CSIC, PO Box 13034, 50080 Zaragoza, Spain
| | - S Vázquez
- Department of Plant Nutrition, Aula Dei Experimental Station, CSIC, PO Box 13034, 50080 Zaragoza, Spain
| | - I D Florez-Sarasa
- Laboratori de Fisiologia Vegetal, Departament de Biologia, Universitat de les Illes Balears, Carretera de Valldemossa, km 7.5, 07071, Palma de Mallorca, Balears, Spain
| | - A Albacete
- Department of Plant Nutrition, CEBAS, CSIC, PO Box 164, 30100 Murcia, Spain
| | - M Ribas-Carbó
- Laboratori de Fisiologia Vegetal, Departament de Biologia, Universitat de les Illes Balears, Carretera de Valldemossa, km 7.5, 07071, Palma de Mallorca, Balears, Spain
| | - J Flexas
- Laboratori de Fisiologia Vegetal, Departament de Biologia, Universitat de les Illes Balears, Carretera de Valldemossa, km 7.5, 07071, Palma de Mallorca, Balears, Spain
| | - J Abadía
- Department of Plant Nutrition, Aula Dei Experimental Station, CSIC, PO Box 13034, 50080 Zaragoza, Spain
| | - F Morales
- Department of Plant Nutrition, Aula Dei Experimental Station, CSIC, PO Box 13034, 50080 Zaragoza, Spain
| |
Collapse
|